Hypercholesterolemia is a well-established risk factor for atherosclerotic cardiovascular disease (ASCVD). How cholesterol and its carrier lipoproteins are involved in ASCVD is still under intensive investigation. Statins are thus far the best-proven class of cholesterol-lowering medications to improve the clinical outcomes of ASCVD. Statins specifically inhibit the rate-limiting enzyme 3-hydroxy-3-methylglutaryl-CoA reductase of the mevalonate pathway for cholesterol biosynthesis. The widely accepted theory is that statins inhibit the hepatic cholesterol synthesis causing upregulation of hepatocyte low-density lipoprotein (LDL) receptor; receptor-mediated LDL uptake and metabolism in the liver results in reduction of circulating LDL cholesterol, which subsequently reduces vascular deposition and retention of cholesterol or LDL in atherogenesis. Nevertheless, cholesterol biosynthesis is ubiquitous, also in extrahepatic cells including those in vascular wall, under tight regulation by sterol regulatory element-binding protein (SREBP), the master gene transcription factor governing cholesterol biosynthesis. Studies have shown that SREBP can be upregulated in vascular wall subject to injury or stent implantation. SREBP can be activated by proinflammatory and mitogenic factors in vascular cells, leading to hyperactive mevalonate pathway, which promotes vascular cell mobilization, further proinflammatory and mitogenic factor release from vascular cells, and vascular inflammation. In this article, we review the cellular cholesterol homeostasis regulation by SREBP and SREBP-mediated vascular hyperactive cholesterol biosynthesis, we term vascular hypercholesterolemia, in the pathogenesis of ASCVD and vasculopathy. SREBP functions as a platform bridging cholesterol, inflammation, and vascular cell mobilization in ASCVD pathogenesis. Targeting vascular hypercholesterolemia could open a new avenue in fighting against ASCVD.

Key Words: atherosclerotic cardiovascular disease, vasculopathy, cholesterol, vascular cell, inflammation, sterol regulatory element-binding protein

From the *Division of Cardiology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; and †Department of Medicine, New York Medical College, Valhalla, NY.

Disclosure: The authors have no conflicts of interest to report.

Correspondence: Ruihai Zhou, MSc, MD, FACC, RPVI, Division of Cardiology, Department of Medicine, University of North Carolina at Chapel Hill, 160 Dental Circle, Campus Box 7075, Chapel Hill, NC 27599-7075. E-mail: ruihai_zhou@med.unc.edu.

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

ISSN: 1061-5377/22/3005-267273
DOI: 10.1097/CRD.0000000000000406

Cholesterol Paradigm and Beyond in Atherosclerotic Cardiovascular Disease

Ruihai Zhou, MSC, MD,* George A. Stouffer, MD,* and William H. Frishman, MD†

Abstract: Hypercholesterolemia is a well-established risk factor for atherosclerotic cardiovascular disease (ASCVD). How cholesterol and its carrier lipoproteins are involved in ASCVD is still under extensive investigation. Statins are thus far the best-proven class of cholesterol-lowering medications to improve the clinical outcomes of ASCVD. Statins specifically inhibit the rate-limiting enzyme 3-hydroxy-3-methylglutaryl-CoA reductase of the mevalonate pathway for cholesterol biosynthesis. The widely accepted theory is that statins inhibit the hepatic cholesterol synthesis causing upregulation of hepatocyte low-density lipoprotein (LDL) receptor; receptor-mediated LDL uptake and metabolism in the liver results in reduction of circulating LDL cholesterol, which subsequently reduces vascular deposition and retention of cholesterol or LDL in atherogenesis. Nevertheless, cholesterol biosynthesis is ubiquitous, also in extrahepatic cells including those in vascular wall, under tight regulation by sterol regulatory element-binding protein (SREBP), the master gene transcription factor governing cholesterol biosynthesis. Studies have shown that SREBP can be upregulated in vascular wall subject to injury or stent implantation. SREBP can be activated by proinflammatory and mitogenic factors in vascular cells, leading to hyperactive mevalonate pathway, which promotes vascular cell mobilization, further proinflammatory and mitogenic factor release from vascular cells, and vascular inflammation. In this article, we review the cellular cholesterol homeostasis regulation by SREBP and SREBP-mediated vascular hyperactive cholesterol biosynthesis, we term vascular hypercholesterolemia, in the pathogenesis of ASCVD and vasculopathy. SREBP functions as a platform bridging cholesterol, inflammation, and vascular cell mobilization in ASCVD pathogenesis. Targeting vascular hypercholesterolemia could open a new avenue in fighting against ASCVD.

Key Words: atherosclerotic cardiovascular disease, vasculopathy, cholesterol, vascular cell, inflammation, sterol regulatory element-binding protein

(© Cardiology in Review 2022:30: 267–273)

In humans, the 27-carbon cholesterol is synthesized with all of the carbon atoms originally from acetate through the MVA pathway.

The enzymes catalyzing the MVA pathway are tightly regulated by the master gene transcription factor, sterol regulatory element-binding protein (SREBP), in response to cellular cholesterol contents and homeostasis not only in hepatic cells but also in nonhepatic ones such as vascular cells (Fig. 1).

In this article, we review cellular cholesterol homeostasis and its regulation by SREBP and role in bridging cholesterol, inflammation, and vascular cell mobilization, and its implication in vasculopathy.
cholesterol but when fed a cholesterol-containing diet, endogenous cholesterol synthesis was no longer observed. This was the first demonstration that an end-product could inhibit a biosynthetic pathway through a feedback mechanism. The feedback regulation of cholesterol biosynthesis is present in various animal species including humans. The mammalian genome harbors 2 SREBP isoform genes, SREBP-1 and SREBP-2. SREBP-1 gene encodes SREBP-1a and SREBP-1c derived from a single gene with different N-termini due to alternative promoters and different first exons. SREBP-1 was first isolated in 1993 by the Goldstein and Brown laboratory when studying cellular cholesterol homeostasis. The group further elucidated the SREBP activation pathway. SREBP-1a activates the genes encoding enzymes for cholesterol biosynthesis, LDL-R, and the enzymes for fatty acid synthesis. SREBP-1c mainly activates the genes for fatty acid synthesis. SREBP-2 is encoded by a different gene, which more specifically activates the genes of the cholesterol biosynthetic enzymes and LDL-R. SREBP can also upregulate themselves at the gene expression level. All 3 SREBP molecules require processing at the protein level for activation (Figs. 1 and 2).

SREBPs are endoplasmic reticulum (ER) membrane-bound, with the N- and C-termini protruding into the cytoplasm and the central hydrophilic domain spanning the ER lumen. In sterol-loaded cells, SREBPs form a complex with the ER membrane-bound SREBP cleavage-activating protein and SREBPs remain inactivated. When the cells sense deficiency in lipids or sterols, SREBP cleavage-activating protein escorts SREBPs from the ER to the Golgi, where SREBPs are cleaved by site 1 and site 2 proteases, a process named activation (Fig. 2). This SREBP activation process is followed by release and subsequent nuclear translocation of the SREBP N-terminal leucine zipper transcription factor to direct the transcriptional activation of target genes including those for the enzymes in MVA pathway, such as HMGCR, as well as LDLR, and fatty acid synthase, among others.

CHOLESTEROL PARADIGM, INFLAMMATION, AND VASCULAR CELL MOBILIZATION, BEYOND CHOLESTEROL IN ASCVD

The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin trial is a randomized placebo-controlled large-scale study investigating the effects of rosuvastatin in traditionally normocholesterolemic, apparently healthy

FIGURE 1. Gene regulation by SREBPs and vascular cell biology in vasculopathy. The diagram shows some of the genes regulated by SREBPs in the biosyntheses of cholesterol and fatty acids and their roles in atherosclerosis and injury-induced neointima formation. SREBP governs cholesterol and fatty acid biosyntheses and homeostasis. In response to proinflammatory or mitogenic factors, SREBP in vascular wall is upregulated (at gene transcription and protein level) and activated at protein level. The cholesterol biosynthesis in vascular cells such as endothelial cells and VSMCs synthesize cholesterol and phospholipids for cell membrane production and for membrane biophysical property adaptation needed for cell migration and proliferation. The cholesterol biosynthesis also produces isoprenoids such as FPP and GGPP for prenylation of small GTPases including Rho, Rac, and CDC42, among others to drive the cytoskeletal dynamics for cell functional change, migration, and proliferation, leading to atherosclerosis or injury-induced neointima formation. AT II indicates angiotensin II; BFGF, basic fibroblast growth factor; FPP, farnesyl diphosphate; GGPP, geranylgeranyl pyrophosphate; GPP, geranylgeranyl pyrophosphate synthase; HMG CoA, 3-hydroxy-3-methylglutaryl-CoA; ILs, interleukins; IPP, isopentenyl diphosphate; LPA, lysophosphatidic acid; PDGF, platelet-derived growth factor; SREBP, sterol regulatory element-binding protein; VEGF, vascular endothelial growth factor; VSMC, vascular smooth muscle cell.
subjects with high levels of inflammatory marker high-sensitivity C-reactive protein (hs-CRP). A total of 17,802 subjects with LDL-C levels below 130 mg/dL (3.4 mmol/L) but hs-CRP levels of 2.0 mg/L or higher were assigned to rosuvastatin or placebo. Rosuvastatin treatment led to a significant reduction in primary endpoint, decreased LDL-C levels by 50% and hs-CRP levels by 37%. Rosuvastatin treatment is considered an inflammatory disease characterized by high blood levels of proinflammatory cytokines. The cholesterol hypothesis implies that hepatic cholesterol biosynthesis is the cause of hypercholesterolemia, and excessive vascular deposition and retention of cholesterol or ApoB-containing lipoproteins from blood circulation drives atherogenesis. However, cholesterol biosynthesis is ubiquitous, not only in hepatic cells but also in vascular wall and other nonhepatic cells. Atherosclerosis or injury-induced neointima formation begins with endothelial cell dysfunction or injury. Mitogenic, chemotactic, and proinflammatory factors from the blood circulation and produced locally by dysfunctional vascular cells and inflammatory cells cause further cell dysfunction such as endothelium layer permeability increase, recruitment of circulating monocytes and lymphocytes to subendothelial space, intimal migration of VSMC from the media, formation of foam cells from macrophages and VSMC, and angiogenesis, culminating in intimal hyperplasia and plaque formation. SREBP plays an important role linking inflammation and cellular cholesterol biosynthesis process in the pathogenesis of vasculopathy. AT II indicates angiotensin II; bFGF, basic fibroblast growth factor; EC, endothelial cell; ER, endoplasmic reticulum; HMG CoAR, 3-hydroxy-3-methylglutaryl-CoA reductase; ILs, interleukins; LDL, low-density lipoprotein; LDL-R, low-density lipoprotein receptor; LPA, lysophosphatidic acid; nSREBP, N-terminal sterol regulatory element-binding protein; PDGF, platelet-derived growth factor; S1P, site-1 protease; S2P, site-2 protease; SCAP, SREBP cleavage-activating protein; SRE, sterol regulatory element; SREBP, sterol regulatory element-binding protein; VEGF, vascular endothelial growth factor; VSMC, vascular smooth muscle cell.

Proinflammatory and Mitogenic Factors Cause Vascular Cell SREBP Activation and Hyperactive Cholesterol Biosynthesis

The cholesterol hypothesis implies that hepatic cholesterol biosynthesis is the cause of hypercholesterolemia, and excessive vascular deposition and retention of cholesterol or ApoB-containing lipoproteins from blood circulation drives atherogenesis. However, cholesterol biosynthesis is ubiquitous, not only in hepatic cells but also in vascular wall and other nonhepatic cells. Atherosclerosis carries pathological features of inflammation. Proinflammatory state with elevated levels of interleukins (ILs) and other inflammatory markers in patients with ASCVD including ACS has been well recognized. Insulin resistance and hyperinsulinemia are a hallmark of type II diabetes mellitus, an equivalent of ASCVD, which is considered an inflammatory disease characterized by high blood levels of proinflammatory cytokines. Studies showed that SREBP could be activated in vascular cells such as endothelial cells (ECs) and vascular smooth muscle cells (VSMCs), by many proinflammatory and mitogenic factors known to be involved in atherosclerosis and neointima formation, such as vascular endothelial growth factor, platelet-derived growth factor, basic fibroblast growth factor, thrombin, IL-8, IL-1β, angiotensin II, insulin, phenylephrine, and lysophosphatidic acid. These factors can be from the systematic circulation or produced locally in the injured vascular wall (Figs. 1 and 2). The SREBP activation is followed by upregulation of its downstream genes such as HMGCR and other enzymes for MVA pathway, LDLR, and enzymes for fatty acid biosynthesis.

SREBP-Mediated Vascular Hyperactive Cholesterol Biosynthesis Promotes Vascular Cell Proliferation and Migration and Vascular Inflammation

Cholesterol and phospholipids are the major components of cell membrane and therefore cholesterol and fatty acid production is needed when a cell divides into daughter cells during proliferation. During cell migration, extension of pseudopodia is followed by cell body movement, membrane detachment, and retraction at the rear edge. During cell migration, such as in ECs, plasma membrane microviscosity increases at the leading edge, and cholesterol enrichment in the front edge is responsible for the generation of this microviscosity gradient, which affects actin function during cell migration.
The MVA pathway is essential in the de novo biosynthesis of cholesterol. MVA is synthesized from 3-hydroxy-3-methylglutaryl-CoA in an irreversible step via the rate-limiting HMGCR and is then further metabolized to the isoprenoids, farnesyl pyrophosphate, and geranylgeranyl pyrophosphate, among other molecules, either as precursors for cholesterol production or as “side products” upstream or away from cholesterol formation (Fig. 1). Isoprenoids farnesyl pyrophosphate and geranylgeranyl pyrophosphate derived from the MVA pathway are critical in the isoprenylation and thus activation of small GTPases (Rho, Ras, Rac, and Cdc42). When isoprenylated, these small GTPases anchor in cell membranes enabling signaling and regulation of actin and other cell cytoskeleton dynamics to form actin stress fibers and provides the driving force of cell movement through actin cytoskeletal processes called lamellipodia and filopodia.27,28 Activated small GTPases also play an important role in inflammatory cell migration into vascular wall and inflammatory mediator production by VSMC, EC, and inflammatory cells in vascular wall.29

Cholesterol biosynthesis process mediated by SREBP and the resultant intermediates may play a role well beyond cholesterol in ASCVD pathogenesis (Fig. 1). Studies showed that SREBP is important in regulating vascular EC function and angiogenesis, both in vitro and in vivo,20,21,24 which is an important process in atheroma formation, inflammation, and post-intervention vascular intimal hyperplasia.29 Angiogenic factors of different classes, such as basic fibroblast growth factor, thrombin, IL-8, insulin, and vascular endothelial growth factor could up regulate the expression and stimulate the activation of SREBP in EC.20,21,24 SREBP-mediated MVA pathway activation and resultant isoprenoids-mediated small GTPase RhoA activation in EC played an indispensable role in vascular EC proliferation, migration, and angiogenesis, as well as increased endothelial layer permeability in response to proinflammatory and mitogenic stimuli. Inhibition of SREBP activation can modify EC behavior resulting in suppression of endothelial migration and proliferation and angiogenesis.20

Aberrant migration of VSMC from medium into intima and proliferation play an important role in atherogenesis and

**FIGURE 3.** SREBP-1 is increased in the neointima following stent placement. A stent was deployed in rat abdominal aortas for 4 weeks. Subsequently, vessels were harvested and analyzed by immunohistochemistry and immunofluorescence. Six μm sections were stained as described below. A, Control normal rat abdominal aorta stained with H&E reveals no neointima but a medial and adventitial (top) layer. B, Immunohistochemical staining for SREBP-1 in normal control untreated rat abdominal aorta is undetectable. C, Following stent placement for 4 weeks, a neointima layer is now visible and robust staining of SREBP-1 is detected. D, Higher magnification of SREBP-1 staining within the neointima. E, Immunofluorescence of FITC-anti-αSMA reveals robust staining within the neointima. F, H&E staining of the abdominal aorta following 4 weeks of stent placement. Reprinted with permission from Zhou et al.22 Copyright American College of Cardiology Foundation. All permission requests for this image should be made to the copyright holder. FITC indicates fluorescein isothiocyanate, H&E, hematoxylin and eosin; NI, neointima; SREBP1, sterol regulatory element-binding protein 1; αSMA, α-smooth muscle actin.
injury-induced intimal hyperplasia in vasculopathy. SREBP can be upregulated in VSMCs as well, at both gene and protein levels in response to multiple stimuli known to cause atherosclerosis, inflammation, and post-intervention restenosis.20–22 The SREBP activation, that is, its cleavage to release N-terminal active protein form, is followed by upregulation of its target gene products involved in cholesterol biosynthesis.20–22 Targeted inhibition of SREBP also led to decreased VSMC migration and proliferation in response to proinflammatory and mitogenic stimuli.22

**VASCULAR HYPERCHOLESTEROLISM AND VASCULOPATHY**

VSMC migration and proliferation, foamy macrophage accumulation, and inflammatory cell infiltration in vascular wall are among the key features of atherosclerosis of the native coronary artery and vein grafts and of the neoatherosclerosis and neointima formation for in-stent restenosis.30,31 In addition to their circulating blood source, inflammatory and mitogenic factors local to the vascular wall also derive from infiltrating inflammatory cells, locally

![Figure 4](image-url)
adhering platelets, and dysfunctional vascular EC and VSMC. These proinflammatory and mitogenic molecules can then activate cellular SREBP and subsequently the MVA pathway for cholesterol biosynthesis. Hyperactive MVA pathway and subsequent accelerated production of pleiotropic molecules cause prenylation and activation of the small GTPases, such as Rho, Rac, CDC42, and Ras proteins, which in turn further promotes proinflammatory cytokine release by vascular cells and increase in endothelial/leukocyte adhesion, endothelial permeability, and inflammatory cell accumulation, as well as in vascular cell migration and proliferation. This self-perpetuating mechanism, composed of inflammatory and mitogenic factors—SREBP activation—MVA pathway—vascular inflammation and cellular mitogenesis—inflammatory and mitogenic factor release—SREBP activation, may play a critical role in the pathogenesis of ASCVD and vasculopathy (Figs. 1 and 2). In injury-induced arterial intimal hyperplasia and in-stent restenosis animal models, SREBP was found to be overexpressed abundantly in arterial wall, strikingly prominent in the VSMCs of the neointima as demonstrated by histological analysis with immunofluorescence and immunohistochemistry studies, reflecting a hyperactive cholesterol biosynthesis mechanism (Figs. 3 and 4).

The hyperactive cellular cholesterol biosynthesis in vascular wall, here we label as vascular hypercholesterolemia, in response to the proinflammatory and mitogenic milieu created by circulating or locally produced factors could play a crucial “pleiotropic” role beyond cholesterol itself in the pathogenesis of ASCVD. Given that the vascular cells are not secretory cells for cholesterol, it is conceivable that vascular hypercholesterolemia would not influence the blood level of cholesterol. The Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial is thus far the only positive trial showing that directly targeting inflammation reduces cardiovascular events without affecting blood LDL-C level. In the CANTOS trial, IL-1β inhibition by canakinumab administration in addition to optimal medical treatment in patients with a history of MI and levels of hs-CRP greater than 2 mg/L led to reduction of hs-CRP levels without affecting the lipid levels and resulted in a 15% reduction in the risk of the primary composite end point of nonfatal MI, nonfatal stroke, or cardiovascular death, as compared with placebo-treated patients. Further analysis showed that in those patients who achieved lower on-treatment hs-CRP concentrations (<2 mg/L), cardiovascular mortality and all-cause mortality were significantly reduced by 31%, whereas these benefits were not observed in those with a hs-CRP concentrations of 2 mg/L or above. Based on the CANTOS trial data, it was found that reduction of the cardiovascular events and total mortality was associated with IL-6 blood level reduction independent of blood lipid level. Of note, IL-1β is among the factors known to activate SREBP and upregulate cholesterol biosynthesis in VSMC. Sirolimus, an immunosuppressant used in renal transplant recipients and in the first generation drug-eluting stents to minimize intimal hyperplasia and reduce repeat revascularization, can inhibit IL-1β–induced SREBP activation and thus endogenous cholesterol synthesis in human VSMC.

CONCLUSIONS

Statins are currently the best-proven cholesterol-lowering medications to improve the clinical outcomes of the patients with ASCVD and their unique mechanism of action suggests that endogenous cholesterol biosynthesis MVA pathway plays an important role in ASCVD. MVA pathway is tightly regulated ubiquitously in all cell types by the master gene, SREBP, for cellular cholesterol homeostasis. SREBP is overexpressed in vascular wall in response to injury or stent implantation and SREBP can be activated in vascular cells, in response to proinflammatory and mitogenic factors causing hyperactive MVA pathway activity, here we termed vascular hypercholesterolemia, as a new concept. SREBP functions as a cross-link platform bridging inflammation, cholesterol biosynthesis, and cell mobilization in vascular wall. Vascular hypercholesterolemia through pleiotropic molecules promotes vascular cell mobilization and further proinflammatory and mitogenic factors production, forming a self-perpetuating mechanism to participate in the pathogenesis of atherosclerosis or vasculopathy (Figs. 1 and 2); therefore, targeting vascular hypercholesterolemia to break the self-perpetuating mechanism could become a new avenue in the prevention and treatment of ASCVD.
22. Zhou RH, Pesant S, Cohn HI, et al. Enhanced sterol response element-binding protein in postintervention restenotic blood vessels plays an important role in vascular smooth muscle proliferation. *Life Sci*. 2008;82:174–181.

23. Ma KL, Varghese Z, Ku Y, et al. Sirolimus inhibits endogenous cholesterol synthesis induced by inflammatory stress in human vascular smooth muscle cells. *Am J Physiol Heart Circ Physiol*. 2010;298:H1646–H1651.

24. Liu Y, Petreaca M, Martins-Green M. Cell and molecular mechanisms of insulin-induced angiogenesis. *J Cell Mol Med*. 2009;13:4492–4504.

25. Vasanji A, Ghosh PK, Graham LM, et al. Polarization of plasma membrane microviscosity during endothelial cell migration. *Dev Cell*. 2004;6:29–41.

26. Ghosh PK, Vasanji A, Murugesan G, et al. Membrane microviscosity regulates endothelial cell motility. *Nat Cell Biol*. 2002;4:894–900.

27. Lamarche N, Tapon N, Stowers L, et al. Rac and Cdc42 induce actin polymerization and G1 cell cycle progression independently of p65PAK and the JNK/SAPK MAP kinase cascade. *Cell*. 1996;87:519–529.

28. Mackay DJ, Esch F, Furthmayr H, et al. Rho- and rac-dependent assembly of focal adhesion complexes and actin filaments in permeabilized fibroblasts: an essential role for ezrin/radixin/moesin proteins. *J Cell Biol*. 1997;138:927–938.

29. Strassheim D, Gerasimovskaya E, Irwin D, et al. RhoGTPase in vascular disease. *Cells*. 2019;8:E551.

30. Zhang M, Cresswell N, Tavora F, et al. In-stent restenosis is associated with neointimal angiogenesis and macrophage infiltrates. *Pathol Res Pract*. 2014;210:1026–1030.

31. Yahagi K, Kolodgie FD, Otuka F, et al. Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis. *Nat Rev Cardiol*. 2016;13:79–98.

32. Helkin A, Stein JJ, Lin S, et al. Dyslipidemia part 1—review of lipid metabolism and vascular cell physiology. *Vasc Endovascular Surg*. 2016;50:107–118.

33. Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. *J Am Coll Cardiol*. 2009;54:2129–2138.

34. Tousoulis D, Psarros C, Demosthenous M, et al. innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. *J Am Coll Cardiol*. 2014;63:2491–2502.

35. Ridker PM, Everett BM, Thuren T, et al; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med*. 2017;377:1119–1131.

36. Ridker PM, MacFadyen JG, Everett BM, et al; CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. *Lancet*. 2018;391:319–328.

37. Ridker PM, Libby P, MacFadyen JG, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). *Eur Heart J*. 2018;39:3499–3507.